Financial insights of ADPT

MyFinsight

Income Statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30
Revenue	71,553	70,874	71,681	93,973
Cost of revenue	20,165	18,708	18,224	18,157
Research and development	19,153	23,623	21,763	23,669
Sales and marketing	26,414	26,346	24,481	23,470
General and administrative	21,168	20,984	19,557	17,959
Amortization of intangible assets	423	419	429	428
Impairment of long-lived assets	-	-	0	0
Total operating expenses	87,323	90,080	84,454	83,683
Loss from operations	-15,770	-19,206	-12,773	10,290
Interest and other income, net	2,256	2,080	2,148	2,226
Interest expense	2,694	2,889	2,954	2,971
Loss on revenue interest liability extinguishment	23,733	-	-	-
Net loss	-39,941	-20,015	-13,579	9,545
Add net loss (income) attributable to noncontrolling interest	-153	18	0	-1
Net loss attributable to adaptive biotechnologies corporation	-39,788	-20,033	-13,579	9,546

Basic EPS	-0.25	-0.13	-0.089	0.06
Diluted EPS	-0.25	-0.13	-0.095	0.06
Basic Average Shares	159,855,257	155,521,048	153,178,137	152,432,307
Diluted Average Shares	159,855,257	155,521,048	142,448,337	163,162,107

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.